Recent and Emerging Therapies for Cutaneous Squamous Cell Carcinomas of the Head and Neck

Varra, Vamsi; Smile, Timothy D.; Geiger, J.L.; Koyfman, Shlomo A.

doi:10.1007/s11864-020-00739-7

Cited by 13 publications

(15 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anti-PD-1 was administered every 3 weeks for two cycles. On 20 enrolled patients, pathologic complete response was obtained in 11 (55%) patients and major pathology response in 3 (15%) patients [182].…”

Section: Neoadjuvant Therapymentioning

confidence: 99%

Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

et al. 2021

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (cSCC), a non-melanoma skin cancer, is a keratinocyte carcinoma representing one of the most common cancers with an increasing incidence. cSCC could be in situ (e.g., Bowen’s disease) or an invasive form. A significant cSCC risk factor is advanced age, together with cumulative sun exposure, fair skin, prolonged immunosuppression, and previous skin cancer diagnoses. Although most cSCCs can be treated by surgery, a fraction of them recur and metastasize, leading to death. cSCC could arise de novo or be the result of a progression of the actinic keratosis, an in situ carcinoma. The multistage process of cSCC development and progression is characterized by mutations in the genes involved in epidermal homeostasis and by several alterations, such as epigenetic modifications, viral infections, or microenvironmental changes. Thus, cSCC development is a gradual process with several histological- and pathological-defined stages. Dermoscopy and reflectance confocal microscopy enhanced the diagnostic accuracy of cSCC. Surgical excision is the first-line treatment for invasive cSCC. Moreover, radiotherapy may be considered as a primary treatment in patients not candidates for surgery. Extensive studies of cSCC pathogenic mechanisms identified several pharmaceutical targets and allowed the development of new systemic therapies, including immunotherapy with immune checkpoint inhibitors, such as Cemiplimab, and epidermal growth factor receptor inhibitors for metastatic and locally advanced cSCC. Furthermore, the implementation of prevention measures has been useful in patient management.

show abstract

Section: Neoadjuvant Therapymentioning

confidence: 99%

Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Advances have been made in recent years regarding systemic cancer therapies, particularly for non-melanoma skin cancers (23,24). This scenario increases the possibility of neoadjuvant options for locally advanced lesions, but more reliable data are still required.…”

Section: ' Discussionmentioning

confidence: 99%

Short-term survival in extensive craniofacial resections

Leite

Alvarenga

Gonçalves

et al. 2021

Clinics

View full text Add to dashboard Cite

Craniofacial resection (CFR) procedures for craniofacial tumors with cranial extension are often extensive. Although CFRs may yield good oncological results, there are concerns about high perioperative morbidity and mortality. This study aimed to determine risk factors for perioperative mortality after open CFR in terms of deaths occurring during index hospitalizations. METHODS: We conducted a retrospective analysis of CFRs conducted at a tertiary oncology hospital from May 2009 through December 2018. RESULTS: Our analysis included data from the medical records of 102 patients, the majority of whom were male (n=74, 72.5%). The mean age was 61 years ( ± 18.3 years). Skin malignancies (n=64, 63.4%) accounted for nearly two-thirds of the treated tumors, and most of these were squamous cell carcinoma. Postoperative medical complications occurred in 33 patients (33%), and surgical complications occurred in 48 (47%). Multivariate analysis revealed the only independent risk factors for perioperative deaths to be the presence of intracranial tumor extension on preoperative imaging (hazard ratio [HR]=4.56; 95% confidence interval [CI]: 1.74-11.97; p=0.002) and the unexpected emergence of postoperative neurological dysfunction (HR=10.9; 95% CI: 2.21-54.3; p=0.003). CONCLUSIONS: In our study, factors related to tumor extension were associated with a higher risk of perioperative death.

show abstract

“…Furthermore, which is certainly no less important, while the side effects of chemotherapy can occur from their first administrations, a complex bioengineering process like the integration of a viral nucleic acid into a host cell, is never fully controllable on a short and long time scale. [17], cutaneous squamous cell carcinoma (cscc) of the head and neck [18],…”

Section: Opinionmentioning

confidence: 99%

Dualism of Viruses in Oncology

Limongi¹

2020

BJSTR

View full text Add to dashboard Cite

Recent and Emerging Therapies for Cutaneous Squamous Cell Carcinomas of the Head and Neck

Cited by 13 publications

References 64 publications

Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

Short-term survival in extensive craniofacial resections

Dualism of Viruses in Oncology

Contact Info

Product

Resources

About